Influenza, Human Clinical Trial
Official title:
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
Verified date | September 3, 2010 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
- Vaccines are substances used to try to create resistance or immunity to a disease and to
prevent an infection. Investigators are looking into improved ways to give and test the
results of different kinds of vaccines.
- Researchers are interested in comparing the results of an experimental DNA vaccine for
the prevention of seasonal influenza against a standard FDA-approved vaccine for the
prevention of seasonal influenza. The experimental DNA vaccine is not yet approved by
the FDA for preventing the flu.
Objectives:
- To test the safety and immune response of an experimental DNA vaccine for seasonal
influenza, compared to the standard vaccine for seasonal influenza.
Eligibility:
- Healthy individuals between ages 45 and 70 who have not yet received the seasonal influenza
vaccine.
Design:
- Participants will have six planned clinic visits (Weeks 0, 1, 3, 4, 6, and 27) and two
telephone follow-up contacts (within 2 days after each injection) during this study.
- Participants will be divided into two groups: one group will receive two standard (TIV)
flu vaccine injections given using a needle and syringe, while the other will receive
the DNA flu vaccine using a needleless injection system followed by the TIV vaccine.
- The vaccine injections for both groups will be given approximately 3 weeks apart,
- Clinic staff will observe participants for at least 30 minutes after each vaccination.
One to two days after each injection, participants must telephone the clinic staff, and
for 7 days after the vaccination participants will keep a diary card to report on
possible side effects.
- During study visits, blood samples will be collected for research purposes to test for
responses to vaccine.
Status | Completed |
Enrollment | 60 |
Est. completion date | September 3, 2010 |
Est. primary completion date | September 3, 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 70 Years |
Eligibility |
- INCLUSION CRITERIA: A SUBJECT MUST MEET ALL OF THE FOLLOWING CRITERIA: 1. 45 to 70 years old. 2. Available for clinical follow-up through Week 27. 3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. 4. Complete an AoU prior to enrollment and verbalize understanding of all questions answered incorrectly. 5. Able and willing to complete the informed consent process. 6. Willing to donate blood for sample storage to be used for future research. 7. No evidence of previously undiagnosed clinically significant chronic diseases. 8. Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) < 42 within the 56 days prior to enrollment. LABORATORY CRITERIA WITHIN 56 DAYS PRIOR TO ENROLLMENT: 9. Hemoglobin greater than or equal to 11.5 g/dL for women; greater than or equal to 13.5 g/dL for men 10. White blood cells (WBC) equal to 3,300-12,000 cells/mm(3) 11. Differential either within institutional normal range or accompanied by site physician approval as a differential that is consistent with healthy volunteer status 12. Total lymphocyte count greater than or equal to 800 cells/mm(3) 13. Platelets equal to 125,000 - 500,000/mm(3) 14. Alanine aminotransferase (ALT) less than or equal to 2.5 times upper limit of normal (ULN) 15. Serum creatinine less than or equal to 1 times ULN (less than or equal to 1.3 mg/dL for females; less than or equal to 1.4 mg/dL for males). 16. Negative FDA-approved HIV blood test. [Note: Results of HIV enzyme-linked immunosorbent assay (ELISA) will be documented, but a negative HIV polymerase chain reaction (PCR) test result will be sufficient for eligibility screening of subjects with positive HIV ELISA that is due to prior participation in an HIV vaccine study]. FEMALE-SPECIFIC CRITERIA: 17. Negative human chorionic gonadotropin (Beta-HCG) pregnancy test (urine or serum) for women presumed to be of reproductive potential on the day of enrollment. 18. A female subject must meet one of the following criteria: - No reproductive potential because of menopause [one year without menses] or because of a hysterectomy, bilateral oophorectomy, or tubal ligation, OR -Agrees to be heterosexually inactive at least 21 days prior to enrollment and through the last study visit, OR - Agrees to consistently practice contraception at least 21 days prior to enrollment and through the last study visit by one of the following methods: - condoms, male or female, with or without a spermicide; - diaphragm or cervical cap with spermicide; - intrauterine device; - contraceptive pills, patch, implant or any other FDA-approved contraceptive method; - male partner has previously undergone a vasectomy. EXCLUSION CRITERIA: A subject will be excluded if one or more of the following conditions apply: Women Specific: 1. Breast-feeding or planning to become pregnant during the 27 weeks after enrollment in the study. Subject has received any of the following substances: 2. Seasonal influenza TIV within the 12 weeks prior to enrollment. 3. Systemic immunosuppressive medications or cytotoxic medications within the 12 weeks prior to enrollment. [With the exceptions that a short course (duration of 10 days or less or a single injection) of corticosteroids for a self-limited condition at least 2 weeks prior to enrollment in this study will not exclude study participation.] 4. Blood products within 112 days (16 weeks) prior to HIV screening 5. Immunoglobulin within 56 days (8 weeks) prior to HIV screening 6. Live attenuated vaccines within 28 days (4 weeks) prior to initial study vaccine administration 7. Investigational research agents within 28 days (4 weeks) prior to initial study vaccine administration 8. Medically indicated subunit or killed vaccines (e.g., pneumococcal, or allergy treatment with antigen injections) within 14 days (2 weeks) of initial study vaccine administration 9. Current anti-TB prophylaxis or therapy Subject has a history of any of the following clinically significant conditions: 10. Contraindication to receiving an FDA approved current seasonal influenza vaccination (e.g., egg allergy). 11. Serious reactions to vaccines that preclude receipt of study vaccinations as determined by investigator. 12. Hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema. 13. Asthma that is severe, unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral, intravenous or high dose inhaled corticosteroids. 14. Diabetes mellitus type I. 15. Thyroid disease that is not well-controlled. 16. Generalized idiopathic urticaria within the last 1 year. 17. Hypertension that is not well controlled by medication or is more than 145/95 at enrollment. 18. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws. 19. Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of the study. 20. Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years. 21. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen. 22. Guillain-Barre Syndrome. 23. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder; disorder requiring lithium; or within 5 years prior to enrollment, a history of suicide plan or attempt. 24. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent. |
Country | Name | City | State |
---|---|---|---|
United States | Clinical Alliance for Research and Education | Annandale | Virginia |
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52. Erratum in: MMWR Recomm Rep. 2009 Aug 21;58(32):896-7. — View Citation
Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis. 2006 Jan;12(1):66-72. Review. — View Citation
Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity. 2006 Jan;24(1):5-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety (local and systemic reactogenicity, lab tests, AEs) | |||
Secondary | Immunogenicity (cellular and humoral immune function assays) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Completed |
NCT03275389 -
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
|
Phase 1 | |
Completed |
NCT05981846 -
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
|
Phase 2 | |
Completed |
NCT05044195 -
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
|
Phase 3 | |
Completed |
NCT02914275 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
|
Phase 3 | |
Completed |
NCT04590066 -
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
|
N/A | |
Recruiting |
NCT03778203 -
Development of Childhood Anti-influenza Immunity
|
Phase 4 | |
Completed |
NCT04527614 -
Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection
|
N/A | |
Terminated |
NCT03658629 -
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
|
Phase 2 | |
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Completed |
NCT02867358 -
A Clinical Trial of KT07 Capsule in the U.S.A
|
Phase 2 | |
Withdrawn |
NCT02883972 -
Childhood Influenza Immunisation Invitation Trial in Schools
|
N/A | |
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Completed |
NCT02998996 -
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
|
Phase 1/Phase 2 | |
Completed |
NCT02545543 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
|
Phase 3 | |
Completed |
NCT02212106 -
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
|
Phase 4 | |
Completed |
NCT02243774 -
Mail Outreach To Increase Vaccination Acceptance Through Engagement
|
N/A | |
Completed |
NCT02621164 -
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
|
Phase 3 | |
Completed |
NCT02344134 -
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects
|
Phase 3 |